• Stimulate bone formation
  • Inhibit bone loss
  • Promotes arterial health
  • Bioavailable form of K2

Vitamin K is most commonly known for its role in blood clotting. Individuals who are taking blood thinning medications must be aware of their vitamin K intake.

One particularly useful form of Vitamin K is K-2 (menaquinone). Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease, as demonstrated in the Rotterdam Study.1

Research shows that vitamin K-2 and its related proteins are critically important for bone health and cardiovascular health. Vitamin K-2 can increase bone formation.2 At the same time, this vitamin decreases bone loss.3,4 The combined effect makes this a perfect nutrient for maintaining bone health and density.

Vitamin K-2 affects proteins in the body that are heavily involved in bone mineralization and vascular health. Reduction in these protein levels has been shown to lead to vascular calcification (a part of atherosclerosis) as well as to bone fractures.5 Individuals with rheumatoid arthritis (RA) typically have lower levels of this nutrient and methods are under development to track vitamin K in clinic studies involving RA and osteoporosis.6

MK-7 is a highly biologically active form of Vitamin K-2.


Other Ingredients:
Rice flour, cellulose (capsule), and silica. 

Contains soy (non-GMO

Do not exceed recommended dose. Pregnant or nursing mothers, children under 18, and individuals with a known medical condition should consult a physician before using this or any dietary supplement.

TRANSCEND's MK-7 contains 60 vcaps per bottle.

Contains no sugar, salt, yeast, wheat, gluten, milk, egg, shellfish or preservatives.

As a dietary supplement, take 1 veggie capsule daily with a meal. Consider taking this product in combination with TRANSCEND's™ Vitamin D and Calcium supplements.


  1. J Nutr. 2004 Nov;134(11):3100-5.
  2. Nutr Rev. 2011 Mar;69(3):162-7. doi: 10.1111/j.1753-4887.2011.00380.x. Epub 2011 Feb 14. Iwamoto J et al.
  3. J Indian Med Assoc. 2010 Apr;108(4):253-4, 256-8. Prabhoo.
  4. Int J Mol Med. 2011 Jan;27(1):3-14. doi: 10.3892/ijmm.2010.562. Epub 2010 Nov 11. Yamaguchi M, Weitzmann MN.
  5.  Curr Vasc Pharmacol. 2011 May 30. Fusaro M. et al. [Epub ahead of print]
  6. Talanta. 2011 Jul 15;85(1):230-6. Epub 2011 Apr 13. Ahmed S. et al.


You recently viewed

Clear recently viewed